ArticleAnnals of medicine2025
Tear neuropeptides are associated with clinical symptoms and signs of dry eye patients.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A comprehensive review of tear fluid proteome alterations in dry eye disease: Insights into pathophysiology and biomarker potential.The ocular surface · 2026Review
- Engineered CGRP Eye Drops Restore Tear Secretion via TRPM8-SSN Circuitry in a Postrefractive Surgery Mouse Model.Investigative ophthalmology & visual science · 2026Article
- Associations of tear mediators with ocular surface symptoms, signs, and corneal nerve morphology in dry eye disease: a cross-sectional study.Frontiers in medicine · 2026Article
- Dry Eye Disease and Psychiatric Disorders: Neuroimmune Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2025Review
- The Immunobiology of Dry Eye Disease: A Review of the Pathogenesis, Regulation and Therapeutic Implications.International journal of molecular sciences · 2025Review
- Long-Term Clinical and Molecular Changes in Dry Eye Disease and Chronic Ocular Pain.International journal of molecular sciences · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate levels of 3 tear-soluble neuropeptides in dry eye patients and to identify the correlations with clinical signs and symptoms.
methodsA total of 16 dry eye patients and 12 healthy volunteers were enrolled. Dry eye disease (DED) diagnosis was based on the 2017 Report of the Tear Film & Ocular Surface Society International Dry Eye Workshop (TFOS DEWS II). First time of noninvasive breakup time (NIBUT-1st), mean time of noninvasive breakup time (NIBUT-avg), tear meniscus height (TMH), Schirmer test, corneal fluorescein staining (CFS) score and ocular surface disease index (OSDI) were recorded. Tear fluid samples were collected and enzyme-linked immunoassay (ELISA was performed to analyze levels of calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY) and substance P (SP), as well as the association among the 3 neuropeptides and clinical findings.
resultsCompared to normal controls, levels of tear CGRP (p=.003) and SP (p=.002) were significantly decreased in dry eye patients yet not NPY concentrations. Levels of tear CGRP and SP showed an inverse correlation with CFS and OSDI, which positively correlated with NIBUT-1st, NIBUT-avg and Schirmer test values. Multiple linear regression analysis showed that Schirmer test values were related to tear CGRP concentration. Subgroup analysis showed lower tear CGRP concentration in DED patients with severe symptoms (OSDI ≥ 46).
conclusionsLevels of tear CGRP and SP decreased in DED patients and showed meaningful correlations with clinical symptoms and signs, implying a potential relationship between tear neuropeptides and ocular neurosensory function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.